J.P. Morgan Reiterates Overweight Rating And Price Target On Cigna (CI)

J.P. Morgan JPM analysts recently met with Cigna's CI management team. They wrote that overall, "the view was optimistic as it relates to the core operations, particularly on performance/outlook for the health and the international segments." Cigna (CI) management expressed the view that their company is less exposed to near term disruptions as a result of the health reform bill than some of their competitors. This outlook is shared by the J.P. Morgan analysts as well. JPM has a price target of $44 on the stock, which they derive by applying a 10x multiple to their 2011 earnings estimates for Cigna. During today's trading session, CI shares have fallen 0.96% to $33.11.